Daxor Corporation (DXR)vsResMed Inc (RMD)
DXR
Daxor Corporation
$11.47
+5.17%
HEALTHCARE · Cap: $58.84M
RMD
ResMed Inc
$218.27
-0.60%
HEALTHCARE · Cap: $31.89B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 21181777% more annual revenue ($5.65B vs $26,690). DXR leads profitability with a 34359.0% profit margin vs 27.0%. DXR trades at a lower P/E of 6.2x. RMD earns a higher WallStSmart Score of 65/100 (C+).
DXR
Hold45
out of 100
Grade: D+
RMD
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DXR.
Margin of Safety
-24.1%
Fair Value
$209.29
Current Price
$218.27
$8.98 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 34359 of every $100 in revenue as profit
Earnings expanding 329.3% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 30.9%
Safe zone — low bankruptcy risk
Every $100 of equity generates 23 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Generating 1.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
Revenue declined 82.6%
Negative free cash flow — burning cash
2.4% earnings growth
Comparative Analysis Report
WallStSmart ResearchBull Case : DXR
The strongest argument for DXR centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 34359.0% and operating margin at -9661.0%.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.0% and operating margin at 30.9%. PEG of 1.33 suggests the stock is reasonably priced for its growth.
Bear Case : DXR
The primary concerns for DXR are Market Cap, Piotroski F-Score, Revenue Growth.
Bear Case : RMD
The primary concerns for RMD are EPS Growth.
Key Dynamics to Monitor
DXR profiles as a declining stock while RMD is a mature play — different risk/reward profiles.
RMD carries more volatility with a beta of 0.77 — expect wider price swings.
RMD is growing revenue faster at 8.6% — sustainability is the question.
RMD generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
RMD scores higher overall (65/100 vs 45/100), backed by strong 27.0% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Daxor Corporation
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?